* CombiChem Inc., of San Diego, and Connect Pharma Ltd., a pharmaceutical consultancy in Oxford, U.K., have entered an agreement for Connect Pharma to exclusively identify European pharmaceutical partners for CombiChem's discovery technology.

* Cytel Corp., of San Diego, and the immunotherapy division of Baxter Healthcare Corp.'s Biotech Group, of Deerfield, Ill., have entered into a clinical research collaboration to develop an ex vivo cancer therapy. Under the collaboration, a Phase I/II pilot study will be initiated to assess the safety and potential effectiveness of treating malignant melanoma patients with tumor-specific cytotoxic T cells produced from patient T cells and activated with peptide epitopes outside the body.